ARID1A and hematopoietic and lymphoid cell neoplasm: Our group showed that ZBTB16-RARA rearranged AML and display several gene mutations commonly identified in AML, including TET2, RUNX1, and CSF3R, and in particular, the most frequent alteration was found in the AT-rich interacting domain containing protein 1A gene (AIRD1A, in 6 out of 7 patients analyzed), a member of the SWI/SNF family of transcriptional regulators, which is a known solid and hematological cancer development driver (26, 111).